<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897595</url>
  </required_header>
  <id_info>
    <org_study_id>P01.014.08/01</org_study_id>
    <nct_id>NCT03897595</nct_id>
  </id_info>
  <brief_title>Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty</brief_title>
  <official_title>A Multi-centre, Prospective Post Marketing Surveillance Study to Assess Mid-term Performance of the Mpact Cup in Subjects Requiring Primary Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medacta USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medacta USA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease
      requiring a total hip replacement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Harris Hip Scores (HHS)</measure>
    <time_frame>Pre-operative, 3 or 6 months, 1 year, 2 year and 5 year</time_frame>
    <description>Assessment of improvement of clinical outcomes following total hip replacement surgery using the Harris Hip Scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of implant survivorship</measure>
    <time_frame>Post-operative 3 or 6 months, 1 year, 2 year, and 5 year</time_frame>
    <description>Assessment of bone fracture, implant fracture, neck reabsorption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline of Complications</measure>
    <time_frame>Day of surgery, post-operative 3 or 6 months, 1 year, 2 year, and 5 year.</time_frame>
    <description>Assessment of Adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline fixation and wear</measure>
    <time_frame>Post-operative 3 or 6 months, 1 year, 2 year and 5 year</time_frame>
    <description>Radiographic analysis by measuring Radio Lucent Lines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline fixation</measure>
    <time_frame>Post-operative 3 or 6 months, 1 year, 2 year and 5 year</time_frame>
    <description>Radiographic analysis by measuring implant fixation in millimeters</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Mpact cup</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head</intervention_name>
    <description>Hip replacement using Medacts's Mpact cup</description>
    <arm_group_label>Mpact cup</arm_group_label>
    <other_name>Hip replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are willing and able to provide written informed consent for
             participation in the study. Written informed consent must be obtained prior to the
             patient's surgery.

               -  Those presenting with disease that meets the indications for use for Medacta USA
                  implants defined by this study (on-label use).

               -  Patients must be willing to comply with the pre and post-operative evaluation
                  schedule

        Exclusion Criteria:

          -  Those with one or more medical conditions identified as a contraindication defined by
             the labeling on any Medacta implants used in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mukesh Ahuja, CPI, MBBS, MS</last_name>
    <phone>312-548-9968</phone>
    <email>mahuja@medacta.us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Denver Vail Orthopedics</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Johnson, MD</last_name>
      <phone>303-925-4750</phone>
      <email>derek@webproze.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Medical Group</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis McGee, MD</last_name>
      <phone>208-367-3330</phone>
    </contact>
    <investigator>
      <last_name>Dennis McGee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Bone and Joint Institute</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Thadani, MD</last_name>
      <phone>847-247-4000</phone>
      <email>pthadani@ibji.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McBride Orthopedic Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tkach, MD</last_name>
      <phone>405-230-9270</phone>
      <email>tomtkach3@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jordan Valley Medical Center of Orthopedics Rehabilitation and Excellence</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Marshall, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

